FDA Clearance Tracker · P910018-S021
LIPOSORBER(R) LA-15 SYSTEM
Last checked: Nov 20, 2026Latest source record: Oct 14, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Oct 14, 2016
Approved
Time to decision
77 days
Received Jul 29, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P910018-S021
- Device name
- LIPOSORBER(R) LA-15 SYSTEM
- Applicant
- Kaneka Pharma America Corp.
- Applicant location
- New York, NY
- Received
- Jul 29, 2016
- Decided
- Oct 14, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P910018
Device type
- Device type
- Lipoprotein, low density, removal (MMY)
- Device class
- Class III
- Specialty
- GI, Urology & Nephrology
FDA's approval statement
As written in FDA's record.
Approval for modifications to the instructions for use, operator's manual, and the patient guide for the LIPOSORBER® LA-15 System for familial hypercholesterolemia and integration of instructions for use for the LIPOSORBER® LA-15 System for familial hypercholesterolemia and focal segmental glomerulosclerosis.
Source documents
Other decisions for Kaneka Pharma America Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.